Investigation whether a switch from oral iron to intravenous ferric carboxymaltose can reduce dose requirements of erythropoiesis-stimulating agents (ESA) and improve Hb levels and iron status in adult patients with non-dialysis-dependent CKD who were on a stable ESA/oral iron schedule for 6 months prior to enrolment.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Ferric carboxymaltose (FCM) dose of 1,000 mg iron, followed by a 6-month ESA/FCM maintenance regimen (target: Hemoglobin 120 g/L, transferrin saturation \>20%)
Hospital Alemán
Buenos Aires, Argentina
ESA dose requirement during the observation period after the switch from oral iron to intravenous ferric carboxymaltose treatment
Time frame: 6 months
Anaemia and iron status
Hemoglobin, mean corpuscular volume, serum ferritin and transferrin saturation were assessed at baseline and monthly until end of study
Time frame: 6 months
Number of hospitalizations
Time frame: 6 months
Number of transfusions
Time frame: 6 months
Number of adverse reactions
Time frame: 6 months
Creatinine clearance at baseline and then bi-monthly until end of study as marker of renal function
Time frame: 6 months
Proteinuria at baseline and then bi-monthly until end of study as marker of renal function
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.